Leitlinie Myokarditis der Deutschen Gesellschaft für Pädiatrische Kardiologie

Zusammenfassung

Diese Leitlinie präsentiert die aktuellen Handlungsanweisungen zur Diagnostik und Therapie der Myokardits im Kindesalter.

Abstract

This consensus statement presents updated recommendations on diagnosis and treatment of myocarditis in childhood

Schlüsselwörter

Myokarditis - Kindesalter - Diagnostik - Therapie

Key words

myocardits - childhood - diagnosis - treatments

• Literatur

• 1 Butts RJ, Boyle GJ, Deshpande SR. et al. Characteristics of Clinically Diagnosed Pediatric Myocarditis in a Contemporary Multi-Center Cohort. Pediatr Cardiol 2017; 38: 1175-1182
• 2 Putschoegl A, Auerbach S. Diagnosis, Evaluation, and Treatment of Myocarditis in Children. Pediatr Clin North Am 2020; 67: 855-874
• 3 Law YM, Lal AK, Chen S. et al. Diagnosis and Management of Myocarditis in Children: A Scientific Statement From the American Heart Association. Circulation 2021; 144: e123-e135
• 4 Wu L, Ong S, Talor MV. et al. Cardiac fibroblasts mediate IL-17A-driven inflammatory dilated cardiomyopathy. J Exp Med 2014; 211: 1449-1464
• 5 Levine MC, Klugman D, Teach SJ. Update on myocarditis in children. Curr Opin Pediatr 2010; 22: 278-283
• 6 Kindermann I, Barth C, Mahfoud F. et al. Update on myocarditis. Journal of the American College of Cardiology 2012; 59: 779-792
• 7 Caforio ALP, Adler Y, Agostini C. et al. Diagnosis and management of myocardial involvement in systemic immune-mediated diseases: a position statement of the European Society of Cardiology Working Group on Myocardial and Pericardial Disease. Eur Heart J 2017; 38: 2649-2662
• 8 Tschope C, Ammirati E, Bozkurt B. et al. Myocarditis and inflammatory cardiomyopathy: current evidence and future directions. Nat Rev Cardiol 2021; 18: 169-193
• 9 Bemtgen X, Klingel K, Hufnagel M. et al. Case Report: Lymphohistiocytic Myocarditis With Severe Cardiogenic Shock Requiring Mechanical Cardiocirculatory Support in Multisystem Inflammatory Syndrome Following SARS-CoV-2 Infection. Front Cardiovasc Med 2021; 8: 716198
• 10 Belhadjer Z, Meot M, Bajolle F. et al. Acute Heart Failure in Multisystem Inflammatory Syndrome in Children in the Context of Global SARS-CoV-2 Pandemic. Circulation 2020; 142: 429-436
• 11 Son MBF, Murray N, Friedman K. et al. Multisystem Inflammatory Syndrome in Children – Initial Therapy and Outcomes. N Engl J Med 2021; 385: 23-34
• 12 Mevorach D, Anis E, Cedar N. et al. Myocarditis after BNT162b2 Vaccination in Israeli Adolescents. N Engl J Med. 2022
• 13 Mevorach D, Anis E, Cedar N. et al. Myocarditis after BNT162b2 mRNA Vaccine against Covid-19 in Israel. N Engl J Med 2021; 385: 2140-2149
• 14 Husby A, Hansen JV, Fosbol E. et al. SARS-CoV-2 vaccination and myocarditis or myopericarditis: population based cohort study. BMJ 2021; 375: e068665
• 15 Canter CE, Simpson KE. Diagnosis and treatment of myocarditis in children in the current era. Circulation 2014; 129: 115-128
• 16 Seidel F, Holtgrewe M, Al-Wakeel-Marquard N. et al. Pathogenic Variants Associated With Dilated Cardiomyopathy Predict Outcome in Pediatric Myocarditis. Circ Genom Precis Med 2021; 14: e003250
• 17 Messroghli DR, Pickardt T, Fischer M. et al. Toward evidence-based diagnosis of myocarditis in children and adolescents: Rationale, design, and first baseline data of MYKKE, a multicenter registry and study platform. Am Heart J 2017; 187: 133-144
• 18 Dieks JK, Backhoff D, Schneider HE. et al. Lone Atrial Flutter in Children and Adolescents: Is It Really “Lone”?. Pediatr Cardiol 2021; 42: 361-369
• 19 Miyake CY, Teele SA, Chen L. et al. In-hospital arrhythmia development and outcomes in pediatric patients with acute myocarditis. The American journal of cardiology 2014; 113: 535-540
• 20 Schubert S, Opgen-Rhein B, Boehne M. et al. Severe heart failure and the need for mechanical circulatory support and heart transplantation in pediatric patients with myocarditis: Results from the prospective multicenter registry “MYKKE”. Pediatr Transplant 2019; 23: e13548
• 21 Arola A, Pikkarainen E, Sipila JO. et al. Occurrence and Features of Childhood Myocarditis: A Nationwide Study in Finland. J Am Heart Assoc 2017; 6: e005306
• 22 Klugman D, Berger JT, Sable CA. et al. Pediatric patients hospitalized with myocarditis: a multi-institutional analysis. Pediatr Cardiol 2010; 31: 222-228
• 23 Kasner M, Aleksandrov A, Escher F. et al. Multimodality imaging approach in the diagnosis of chronic myocarditis with preserved left ventricular ejection fraction (MCpEF): The role of 2D speckle-tracking echocardiography. Int J Cardiol 2017; 243: 374-378
• 24 Paulus WJ, Tschope C, Sanderson JE. et al. How to diagnose diastolic heart failure: a consensus statement on the diagnosis of heart failure with normal left ventricular ejection fraction by the Heart Failure and Echocardiography Associations of the European Society of Cardiology. Eur Heart J 2007; 28: 2539-2550
• 25 Gursu HA. Cetin, II, Azak E et al. The assessment of treatment outcomes in patients with acute viral myocarditis by speckle tracking and tissue Doppler methods. Echocardiography 2019; 36: 1666-1674
• 26 Kasner M, Gaub R, Sinning D. et al. Global strain rate imaging for the estimation of diastolic function in HFNEF compared with pressure-volume loop analysis. Eur J Echocardiogr 2010; 11: 743-751
• 27 Wisotzkey BL, Soriano BD, Albers EL. et al. Diagnostic role of strain imaging in atypical myocarditis by echocardiography and cardiac MRI. Pediatr Radiol 2018; 48: 835-842
• 28 Jhamnani S, Fuisz A, Lindsay J. The spectrum of electrocardiographic manifestations of acute myocarditis: an expanded understanding. J Electrocardiol 2014; 47: 941-947
• 29 Ichikawa R, Sumitomo N, Komori A. et al. The follow-up evaluation of electrocardiogram and arrhythmias in children with fulminant myocarditis. Circ J 2011; 75: 932-938
• 30 Cooper LT. Myocarditis. N Engl J Med 2009; 360: 1526-1538
• 31 Durani Y, Egan M, Baffa J. et al. Pediatric myocarditis: presenting clinical characteristics. Am J Emerg Med 2009; 27: 942-947
• 32 Messroghli DR, Moon JC, Ferreira VM. et al. Clinical recommendations for cardiovascular magnetic resonance mapping of T1, T2, T2* and extracellular volume: A consensus statement by the Society for Cardiovascular Magnetic Resonance (SCMR) endorsed by the European Association for Cardiovascular Imaging (EACVI). J Cardiovasc Magn Reson 2017; 19: 75
• 33 Ferreira VM, Schulz-Menger J, Holmvang G. et al. Cardiovascular Magnetic Resonance in Nonischemic Myocardial Inflammation: Expert Recommendations. Journal of the American College of Cardiology 2018; 72: 3158-3176
• 34 Pitak B, Opgen-Rhein B, Schubert S. et al. Cardiovascular magnetic resonance in children with suspected myocarditis: current practice and applicability of adult protocols. Cardiology in the young 2022; 1-9
• 35 Caforio AL, Pankuweit S, Arbustini E. et al Current state of knowledge on aetiology, diagnosis, management, and therapy of myocarditis: a position statement of the European Society of Cardiology Working Group on Myocardial and Pericardial Diseases. Eur Heart J 2013; 34: 2636-2648 2648a-2648d
• 36 Seferovic PM, Tsutsui H, McNamara DM. et al. Heart Failure Association, Heart Failure Society of America, and Japanese Heart Failure Society Position Statement on Endomyocardial Biopsy. J Card Fail 2021; 27: 727-743
• 37 Pollack A, Kontorovich AR, Fuster V. et al. Viral myocarditis – diagnosis, treatment options, and current controversies. Nat Rev Cardiol 2015; 12: 670-680
• 38 Mueller GC, Michel-Behnke I, Knirsch W. et al. Feasibility, safety and diagnostic impact of endomyocardial biopsies for the diagnosis of myocardial disease in children and adolescents. EuroIntervention 2018; 14: 1089-1095
• 39 Pophal SG, Sigfusson G, Booth KL. et al. Complications of endomyocardial biopsy in children. Journal of the American College of Cardiology 1999; 34: 2105-2110
• 40 Frey T, Arain N. Pediatric Viral Myocarditis – A Review. S D Med 2018; 71: 29-34
• 41 Pankuweit S, Klingel K. Viral myocarditis: from experimental models to molecular diagnosis in patients. Heart Fail Rev 2013; 18: 683-702
• 42 Degener F, Salameh A, Manuylova T. et al. First paediatric cohort for the evaluation of inflammation in endomyocardial biopsies derived from congenital heart surgery. Int J Cardiol 2020; 303: 36-40
• 43 Bultmann BD, Sotlar K, Klingel K. Parvovirus B19. N Engl J Med 2004; 350: 2006-2007 author reply 2006-7
• 44 Bock CT, Klingel K, Kandolf R. Human parvovirus B19-associated myocarditis. N Engl J Med 2010; 362: 1248-1249
• 45 Elsanhoury A, Kühl U, Stautner B. et al. The Spontaneous Course of Human Herpesvirus 6 DNA-Associated Myocarditis and the Effect of Immunosuppressive Intervention. Viruses 2022; 14: 299
• 46 Tschope C, Elsanhoury A, Schlieker S. et al. Immunosuppression in inflammatory cardiomyopathy and parvovirus B19 persistence. Eur J Heart Fail 2019; 21: 1468-1469
• 47 Soler-Botija C, Galvez-Monton C, Bayes-Genis A. Epigenetic Biomarkers in Cardiovascular Diseases. Front Genet 2019; 10: 950
• 48 Halliday BP, Cleland JGF, Goldberger JJ. et al. Personalizing Risk Stratification for Sudden Death in Dilated Cardiomyopathy: The Past, Present, and Future. Circulation 2017; 136: 215-231
• 49 Shah SJ, Katz DH, Selvaraj S. et al. Phenomapping for novel classification of heart failure with preserved ejection fraction. Circulation 2015; 131: 269-279
• 50 Kannan S, Miyamoto M, Lin BL. et al. Large Particle Fluorescence-Activated Cell Sorting Enables High-Quality Single-Cell RNA Sequencing and Functional Analysis of Adult Cardiomyocytes. Circ Res 2019; 125: 567-569
• 51 Mahfoud F, Gartner B, Kindermann M. et al. Virus serology in patients with suspected myocarditis: utility or futility?. Eur Heart J 2011; 32: 897-903
• 52 Pelliccia A, Sharma S, Gati S. et al. 2020 ESC Guidelines on sports cardiology and exercise in patients with cardiovascular disease. Eur Heart J 2021; 42: 17-96
• 53 Michel-Behnke I, Thul J, Murin P. et al. Leitlinie DGPK: Akute Herzinsuffizienz und mechanische Kreislaufunterstützung. https://wwwdgpkorg/fileadmin/user_upload/Leitlinien/LLAHI_2020-finalpdf 2020
• 54 Tschope C, Van Linthout S, Jager S. et al. Modulation of the acute defence reaction by eplerenone prevents cardiac disease progression in viral myocarditis. ESC Heart Fail 2020; 7: 2838-2852
• 55 Solomon SD, McMurray JJV, Anand IS. et al. Angiotensin-Neprilysin Inhibition in Heart Failure with Preserved Ejection Fraction. N Engl J Med 2019; 381: 1609-1620
• 56 Rickers C, Läer S, Diller GP. et al. Leitlinie DGPK: Chronische Herzinsuffizienz. https://wwwdgpkorg/fileadmin/user_upload/Leitlinien/LL_Chronische_Herzinsuffizienz_Nov_2015_Rickerspdf 2015
• 57 Paul T, Ruschewski W, Janousek J. Leitlinie DGPK: Bradykarde Herzrhythmusstörungen im Kindes- und Jugendalter sowie bei jungen Erwachsenen mit einem angeborenen Herzfehler (EMAH). https://wwwdgpkorg/fileadmin/user_upload/Leitlinien/2019_09_04_LL-Bradykardie_finalpdf 2019
• 58 Paul T, Gebauer R, Kriebel T. et al. Leitlinie DGKP: Tachykarde Herzrhythmusstörungen. https://wwwdgpkorg/fileadmin/user_upload/Leitlinien/Leitlinie_Tachykardien_DGPK_2018_11_28_finalpdf 2018
• 59 Janousek J, Ruschewski W, Paul T. Leitlinie DGPK: Leitlinie Pädiatrische Kardiologie: Ventrikuläre Tachykardien und Prävention des plötzlichen Herztodes – Indikationen zur ICD Therapie. https://wwwdgpkorg/fileadmin/user_upload/Leitlinien/2019_04_10_Beschluss_LL-ICD-04-04-2019__2_pdf 2019
• 60 Maisch B, Pankuweit S. Inflammatory dilated cardiomyopathy : Etiology and clinical management. Herz 2020; 45: 221-229
• 61 Bhatt GC, Sankar J, Kushwaha KP. Use of intravenous immunoglobulin compared with standard therapy is associated with improved clinical outcomes in children with acute encephalitis syndrome complicated by myocarditis. Pediatr Cardiol 2012; 33: 1370-1376
• 62 Robinson JL, Hartling L, Crumley E. et al. A systematic review of intravenous gamma globulin for therapy of acute myocarditis. BMC Cardiovasc Disord 2005; 5: 12
• 63 Drucker NA, Colan SD, Lewis AB. et al. Gamma-globulin treatment of acute myocarditis in the pediatric population. Circulation 1994; 89: 252-257
• 64 Heidendael JF, Den Boer SL, Wildenbeest JG. et al. Intravenous immunoglobulins in children with new onset dilated cardiomyopathy. Cardiology in the young 2018; 28: 46-54
• 65 Haque A, Bhatti S, Siddiqui FJ. Intravenous immune globulin for severe acute myocarditis in children. Indian Pediatr 2009; 46: 810-811
• 66 Robinson J, Hartling L, Vandermeer B. et al. Intravenous immunoglobulin for presumed viral myocarditis in children and adults. Cochrane Database Syst Rev 2020; 8: CD004370
• 67 Hazebroek MR, Henkens M, Raafs AG. et al. Intravenous immunoglobulin therapy in adult patients with idiopathic chronic cardiomyopathy and cardiac parvovirus B19 persistence: a prospective, double-blind, randomized, placebo-controlled clinical trial. Eur J Heart Fail 2021; 23: 302-309
• 68 Kandolf R. [Diagnosis of myocarditis]. Dtsch Med Wochenschr 2011; 136: 829-835
• 69 Tschope C, Muller I, Xia Y. et al. NOD2 (Nucleotide-Binding Oligomerization Domain 2) Is a Major Pathogenic Mediator of Coxsackievirus B3-Induced Myocarditis. Circ Heart Fail 2017; 10
• 70 De Luca G, Cavalli G, Campochiaro C. et al. Myocarditis: An Interleukin-1-Mediated Disease?. Front Immunol 2018; 9: 1335
• 71 Luconi N, Risse J, Busato T. et al. Myocarditis in a young man with adult onset Still’s disease successfully treated with Il-1 blocker. Int J Cardiol 2015; 189: 220-222
• 72 Henderson LA, Canna SW, Friedman KG. et al. American College of Rheumatology Clinical Guidance for Multisystem Inflammatory Syndrome in Children Associated With SARS-CoV-2 and Hyperinflammation in Pediatric COVID-19: Version 2. Arthritis Rheumatol 2021; 73: e13-e29
• 73 Harwood R, Allin B, Jones CE. et al. A national consensus management pathway for paediatric inflammatory multisystem syndrome temporally associated with COVID-19 (PIMS-TS): results of a national Delphi process. Lancet Child Adolesc Health 2021; 5: 133-141
• 74 Muller J, Wallukat G, Dandel M. et al. Immunoglobulin adsorption in patients with idiopathic dilated cardiomyopathy. Circulation 2000; 101: 385-391
• 75 Wallukat G, Muller J, Hetzer R. Specific removal of beta1-adrenergic autoantibodies from patients with idiopathic dilated cardiomyopathy. N Engl J Med 2002; 347: 1806
• 76 Ameling S, Bhardwaj G, Hammer E. et al. Changes of myocardial gene expression and protein composition in patients with dilated cardiomyopathy after immunoadsorption with subsequent immunoglobulin substitution. Basic Res Cardiol 2016; 111: 53
• 77 Costanzo-Nordin MR, Reap EA, O’Connell JB. et al. A nonsteroid anti-inflammatory drug exacerbates Coxsackie B3 murine myocarditis. Journal of the American College of Cardiology 1985; 6: 1078-1082
• 78 Adler Y, Charron P, Imazio M. et al. 2015 ESC Guidelines for the diagnosis and management of pericardial diseases: The Task Force for the Diagnosis and Management of Pericardial Diseases of the European Society of Cardiology (ESC)Endorsed by: The European Association for Cardio-Thoracic Surgery (EACTS). Eur Heart J 2015; 36: 2921-2964
• 79 Schultheiss HP, Piper C, Sowade O. et al. Betaferon in chronic viral cardiomyopathy (BICC) trial: Effects of interferon-beta treatment in patients with chronic viral cardiomyopathy. Clin Res Cardiol 2016; 105: 763-773
• 80 Escher F, Kuhl U, Lassner D. et al. Long-term outcome of patients with virus-negative chronic myocarditis or inflammatory cardiomyopathy after immunosuppressive therapy. Clin Res Cardiol 2016; 105: 1011-1020
• 81 Merken J, Hazebroek M, Van Paassen P. et al. Immunosuppressive Therapy Improves Both Short- and Long-Term Prognosis in Patients With Virus-Negative Nonfulminant Inflammatory Cardiomyopathy. Circ Heart Fail 2018; 11: e004228
• 82 Frustaci A, Russo MA, Chimenti C. Randomized study on the efficacy of immunosuppressive therapy in patients with virus-negative inflammatory cardiomyopathy: the TIMIC study. Eur Heart J 2009; 30: 1995-2002
• 83 Gagliardi MG, Bevilacqua M, Bassano C. et al. Long term follow up of children with myocarditis treated by immunosuppression and of children with dilated cardiomyopathy. Heart 2004; 90: 1167-1171
• 84 Aziz KU, Patel N, Sadullah T. et al. Acute viral myocarditis: role of immunosuppression: a prospective randomised study. Cardiology in the young 2010; 20: 509-515
• 85 Camargo PR, Okay TS, Yamamoto L. et al. Myocarditis in children and detection of viruses in myocardial tissue: implications for immunosuppressive therapy. Int J Cardiol 2011; 148: 204-208
• 86 He B, Li X, Li D. Immunosuppressive Treatment for Myocarditis in the Pediatric Population: A Meta-Analysis. Front Pediatr 2019; 7: 430
• 87 Hetzer R, Stiller B. Technology insight: Use of ventricular assist devices in children. Nat Clin Pract Cardiovasc Med 2006; 3: 377-386
• 88 Spillmann F, Van Linthout S, Schmidt G. et al. Mode-of-action of the PROPELLA concept in fulminant myocarditis. Eur Heart J 2019; 40: 2164-2169
• 89 Schmaltz AA, Demel KP, Kallenberg R. et al. Immunosuppressive therapy of chronic myocarditis in children: three cases and the design of a randomized prospective trial of therapy. Pediatr Cardiol 1998; 19: 235-239
• 90 Pelliccia A, Solberg EE, Papadakis M. et al. Recommendations for participation in competitive and leisure time sport in athletes with cardiomyopathies, myocarditis, and pericarditis: position statement of the Sport Cardiology Section of the European Association of Preventive Cardiology (EAPC). Eur Heart J 2019; 40: 19-33
• 91 Maron BJ, Udelson JE, Bonow RO. et al. Eligibility and Disqualification Recommendations for Competitive Athletes With Cardiovascular Abnormalities: Task Force 3: Hypertrophic Cardiomyopathy, Arrhythmogenic Right Ventricular Cardiomyopathy and Other Cardiomyopathies, and Myocarditis: A Scientific Statement From the American Heart Association and American College of Cardiology. Circulation 2015; 132: e273-e280
• 92 Gati S, Sharma S, Pennell D. The Role of Cardiovascular Magnetic Resonance Imaging in the Assessment of Highly Trained Athletes. JACC Cardiovasc Imaging 2018; 11: 247-259